Skip to main content
Caplight Logo









NVision

NVision

Private
Ulm, Baden-WürttembergHealthcare & Life Scienceshttps://nvision-quantum.com

Last Round

Series B

May 13, 2026

Est. Valuation

$250M

Total Funding Raised

$194.3M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

NVision is a quantum technology company that develops quantum-based systems for healthcare, including quantum-enhanced MRI for metabolic imaging and quantum computing for drug discovery.

Sector

Healthcare & Life Sciences

Verticals

Medical Imaging, Quantum Computing, Drug Discovery, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales, Data as a Service, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

metabolic imaginghyperpolarizationquantum-enhanced MRIquantum polarizermetabolic MRIquantum sensingtreatment response monitoringquantum computingdrug discoveryphotonic integrated quantum circuitsPIQConcology imagingmedical imaging equipmentnon-invasive diagnosticsconsumable kits

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NVision Comparables

Compare NVision with similar companies based on industry and business-model similarity.

NVision comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GE HealthCare Technologies Inc.
75%
Bruker
74%
Polarean Imaging
70%

NVision Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 13, 2026
Series BMay 13, 2026
GrantMar 16, 2026
Series BMay 13, 2024
Series AJun 22, 2023

Key People

Founding team and executive leadership

Sella Brosh

Chief Executive Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 13, 2026

    $55M round led by Abbott Laboratories.

  • May 13, 2026

    $55M round led by Abbott Laboratories

Recent news

Latest coverage and updates

  • partners_withSep 1, 2026

    Nvision Quantum partnered with Memorial Sloan Kettering Cancer Center on Sep 1st '26.

NVision Filings

Explore SEC and related filing metadata, where available.

NVision filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NVision's valuation, stock price, and market status.

Is NVision a public or private company?

NVision is a private company.

What is the current stock price of NVision?

NVision is a private company with no public stock price. No recent secondary market data is available.

How much is NVision worth (valuation)?

NVision's valuation is estimated at $250.0M based on funding round data.

Can I buy NVision stock?

NVision shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was NVision's last funding round?

NVision's most recent funding round was Series B on May 13, 2026.

Who are the main investors in NVision?

Key investors in NVision include Playground Global.

Will NVision IPO soon?

No public IPO plans have been announced for NVision.

How can I track NVision secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NVision's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersUlm, Baden-Württemberg
Employee Range101
Year Founded2015
Last FundingMay 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?